Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
GILT Docetaxel - Non-Small Cell Lung Cancer
- Conditions
- Lung Neoplasms
- Interventions
- Drug: docetaxel/gemcitabineDrug: Docetaxel/DDP
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 449
- Registration Number
- NCT00174629
- Locations
- 🇨🇭
Sanofi-Aventis, Genève, Switzerland
Study of Docetaxel in Breast Cancer Patients
- Conditions
- Breast Neoplasms
- Interventions
- Drug: epidoxorubicine, docetaxel, cyclophosphamideDrug: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracileDrug: epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 998
- Registration Number
- NCT00174707
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 97
- Registration Number
- NCT00160030
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 582
- Registration Number
- NCT00135941
- Locations
- 🇺🇸
Advanced Healthcare, Milwaukee, Wisconsin, United States
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: TeriflunomideDrug: Placebo (for teriflunomide)
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1088
- Registration Number
- NCT00134563
- Locations
- 🇨🇦
sanofi-aventis, Canada, Laval, Canada
🇸🇪Sanofi-Aventis, Bromma, Sweden
🇩🇪Sanofi-Aventis Deutschland GmbH, Berlin, Germany
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 281
- Registration Number
- NCT00135057
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 347
- Registration Number
- NCT00135083
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00135096
- Locations
- 🇺🇸
Sanofi-aventis, Bridgewater, New Jersey, United States
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2008-07-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 947
- Registration Number
- NCT00133731
- Locations
- 🇺🇸
Los Angeles Cardiology Associates, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
- Conditions
- Rhinitis, Allergic, Perennial
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 460
- Registration Number
- NCT00132925
- Locations
- 🇺🇸
Sanofi-Aventis, Inc., Bridgewater, New Jersey, United States